| HOME >> BIOLOGY >> TECHNOLOGY |
of these individual items:
-- Acquisition-related charges -- These adjustments primarily consist of
purchased research and development, integration costs associated with
the Company's acquisition of Guidant, and a fair value adjustment
related to the sharing of proceeds feature of the Abbott stock
purchase. Purchased research and development is a highly variable
charge based on valuation assumptions. Management removes the impact of
purchased research and development from the Company's operating results
to assist in assessing the Company's operating performance and cash
generated from operations. The integration costs associated with the
Company's acquisition of Guidant do not reflect expected on-going
future operating expenses. The fair value adjustment related to the
sharing of proceeds feature of the Abbott stock purchase is a non-cash
adjustment and is not indicative of the Company's on-going operations.
Accordingly, management excluded these charges for purposes of
calculating these non-GAAP measures to facilitate an evaluation of the
Company's current operating performance and a comparison to the
Company's past operating performance.
-- Gain on divestitures -- These gains are not indicative of future
operating performance and are not used by management to assess
operating performance. Accordingly, management excluded these amounts
for purposes of calculating these non-GAAP measures to facilitate an
evaluation of the Company's current operating performance and a
comparison to the Company's past operating performance.
-- Restructuring-related charges -- These adjustments primarily represent
employee-related termination benefits, asset write-downs and other
costs associated with the Company's restructuring initiati
'/>"/>
| SOURCE Boston Scientific Corporation Copyright©2008 PR Newswire. All rights reserved |